Gileads ZUMA3 study shows continued efficacy and results from tweaks to side effect management

Gilead’s ZUMA-3 study shows continued efficacy, and results from tweaks to side effect management

The company presented end-of-Phase I data from the trial, on KTE-X19, at the ASCO meeting in Chicago Saturday.

More From BioPortfolio on "Gilead’s ZUMA-3 study shows continued efficacy, and results from tweaks to side effect management"